EyeControl

EyeControl is a medical technology company specializing in AI-driven eye-tracking communication solutions primarily for patients who cannot speak, such as those with ALS or locked-in syndrome. Their flagship product is a wearable eye-tracking headset paired with a cloud-based platform that converts eye gestures into communication and clinical data, serving critical care units (ICUs) and home-care patients. EyeControl aims to improve patient engagement, reduce ICU delirium, and enhance clinical outcomes by bridging communication gaps between patients, caregivers, and families[1][2][5].

Founded in 2016 in Tel Aviv, Israel, EyeControl was established by co-founders with personal connections to locked-in syndrome, including CEO Or Retzkin and CTO Itai Kornberg. The idea originated from the need to restore communication for ALS patients and evolved to address broader ICU patient populations after recognizing the larger market and clinical impact potential. Early traction included support from Israel’s largest health fund, Clalit, and partnerships with medical teams, with recent funding rounds including European Bank and Google AI Fund investments[2][3][4].

Core Differentiators

• Product innovation: First screen-free, eye-controlled communication device that is lightweight, adjustable, and designed for extended ICU use with minimal interference with medical equipment[3][5].
• AI-driven platform: Integrates eye-tracking data with patient engagement tools, including family messaging apps and near-bed tablets for real-time communication and clinical monitoring[5].
• User-centric design: Prioritizes patient comfort and ease of use for medical staff, employing bone conduction audio technology for clear communication even in noisy ICU environments[5].
• Market focus: Transitioned from a niche ALS device to a scalable solution for critical care and home-care markets, addressing a $5 billion potential market[2][3].

Role in the Broader Tech Landscape

EyeControl rides the growing trend of AI and wearable technologies transforming healthcare, particularly in critical care communication and patient monitoring. The timing is crucial as ICUs seek to reduce costly complications like delirium and improve patient outcomes through enhanced engagement. EyeControl’s technology aligns with increasing demand for non-invasive, patient-centered solutions that integrate seamlessly into clinical workflows, influencing broader adoption of AI-driven assistive devices in healthcare[2][5].

Quick Take & Future Outlook

EyeControl is poised to expand its footprint beyond Israel into the US and other markets, leveraging clinical validation and strategic partnerships. Future trends shaping its journey include advances in AI, increased ICU digitalization, and growing awareness of the importance of patient communication in recovery. As EyeControl scales, it may evolve from a communication aid to a comprehensive ICU patient engagement platform, potentially influencing standards of critical care globally[2][5].

EyeControl’s mission to restore voice and agency to non-verbal patients encapsulates a transformative vision for healthcare communication, making it a compelling player at the intersection of AI, medical devices, and patient-centered care.